Core Viewpoint - The company, Meis Health (02415.HK), anticipates a significant increase in shareholder profit for the six months ending June 30, 2025, projecting at least RMB 10 million, compared to a mere RMB 200,000 for the same period in 2024 [1] Group 1: Profit Forecast - The expected profit increase is primarily attributed to the recovery in the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models, which has led to a rise in demand for precise omnichannel marketing solutions [1] - The application of artificial intelligence is enhancing production efficiency across various business segments of the company [1] - The active implementation of environmental, social, and governance (ESG) principles is enabling the company to control operational costs more effectively [1]
梅斯健康(02415.HK)盈喜：预期中期股东应占溢利不少于1000万元